These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35257517)

  • 1. A modified version of the interlocking finger test as a bedside screening test for visuospatial deficits and dementia in Parkinson's disease.
    Schmidt N; Strohmaier T; Witt K
    Brain Behav; 2022 Apr; 12(4):e2516. PubMed ID: 35257517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interlocking finger test in patients with Parkinson's disease and healthy subjects.
    Souza CP; Oliveira GN; Foss MP; Tumas V
    J Clin Neurosci; 2016 Jul; 29():145-8. PubMed ID: 26960261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cognitive impairment in Parkinson's disease].
    Tachibana H
    Seishin Shinkeigaku Zasshi; 2013; 115(11):1142-9. PubMed ID: 24450147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which figure copy test is more sensitive for cognitive impairment in Parkinson's disease: Wire cube or interlocking pentagons?
    Alty JE; Cosgrove J; Jamieson S; Smith SL; Possin KL
    Clin Neurol Neurosurg; 2015 Dec; 139():244-6. PubMed ID: 26519897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domain specific cognitive impairment in Parkinson's patients with mild cognitive impairment.
    Chaudhary S; Kumaran SS; Kaloiya GS; Goyal V; Sagar R; Kalaivani M; Jaganathan NR; Mehta N; Srivastava A
    J Clin Neurosci; 2020 May; 75():99-105. PubMed ID: 32192853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficit in specific cognitive domains associated with dementia in Parkinson's disease.
    Pal A; Pegwal N; Kaur S; Mehta N; Behari M; Sharma R
    J Clin Neurosci; 2018 Nov; 57():116-120. PubMed ID: 30150061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A time-efficient screening tool for activities of daily living functions in Parkinson's disease dementia.
    Sulzer P; Liebig L; Csoti I; Graessel E; Wurster I; Berg D; Liepelt-Scarfone I
    J Clin Exp Neuropsychol; 2020 Oct; 42(8):867-879. PubMed ID: 33043797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in
    Wu L; Liu FT; Ge JJ; Zhao J; Tang YL; Yu WB; Yu H; Anderson T; Zuo CT; Chen L; Wang J
    Hum Brain Mapp; 2018 Dec; 39(12):4652-4662. PubMed ID: 29999569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales.
    Gasser AI; Calabrese P; Kalbe E; Kessler J; Rossier P
    Rev Neurol (Paris); 2016 Feb; 172(2):138-45. PubMed ID: 26494570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive impairment in early-stage non-demented Parkinson's disease patients.
    Pfeiffer HC; Løkkegaard A; Zoetmulder M; Friberg L; Werdelin L
    Acta Neurol Scand; 2014 May; 129(5):307-18. PubMed ID: 24117192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CERAD test performance and cognitive impairment in Parkinson's disease.
    Karrasch M; Laatu S; Martikainen K; Marttila R
    Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Six-item Clock-Drawing Scoring System: a rapid screening for cognitive impairment in Parkinson's disease.
    Lolekha P; Tangkanakul C; Saengchatri T; Kulkeartprasert P
    Psychogeriatrics; 2021 Jan; 21(1):24-31. PubMed ID: 32875700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease.
    Biundo R; Weis L; Pilleri M; Facchini S; Formento-Dojot P; Vallelunga A; Antonini A
    J Neural Transm (Vienna); 2013 Apr; 120(4):627-33. PubMed ID: 23483334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment.
    Devignes Q; Bordier C; Viard R; Defebvre L; Kuchcinski G; Leentjens AFG; Lopes R; Dujardin K
    Mov Disord; 2022 Mar; 37(3):502-512. PubMed ID: 34918782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
    Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
    Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the Montreal Cognitive Assessment (MoCA) identify cognitive impairment profiles in Parkinson's disease? An exploratory study.
    Castelli MB; Alonso-Recio L; Carvajal F; Serrano JM
    Appl Neuropsychol Adult; 2024; 31(3):238-247. PubMed ID: 34894908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition.
    Wojtala J; Heber IA; Neuser P; Heller J; Kalbe E; Rehberg SP; Storch A; Linse K; Schneider C; Gräber S; Berg D; Dams J; Balzer-Geldsetzer M; Hilker-Roggendorf R; Oberschmidt C; Baudrexel S; Witt K; Schmidt N; Deuschl G; Mollenhauer B; Trenkwalder C; Liepelt-Scarfone I; Spottke A; Roeske S; Wüllner U; Wittchen HU; Riedel O; Dodel R; Schulz JB; Reetz K
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):171-179. PubMed ID: 30297519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.
    Burdick DJ; Cholerton B; Watson GS; Siderowf A; Trojanowski JQ; Weintraub D; Ritz B; Rhodes SL; Rausch R; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Srivatsal S; Edwards KL; Montine TJ; Zabetian CP; Leverenz JB
    Mov Disord; 2014 Sep; 29(10):1258-64. PubMed ID: 25073717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.
    Garcia-Garcia D; Clavero P; Gasca Salas C; Lamet I; Arbizu J; Gonzalez-Redondo R; Obeso JA; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1767-77. PubMed ID: 22872307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.